The Boston Biomarker & CDx Summit

Pharmaceutical companies are investing heavily in targeted medicines, and with good reason. However, to increase the probability of a drug making it from Phase I to market and to succeed in developing targeted medicines, companies need robust and efficient biomarker strategies. As a result, Identification of biomarkers that can be studied throughout the development process requires technologies that are both feasible and cost-effective for large patient populations.

Against this background, The Boston Biomarker and CDx Summit taking place on 24th - 25th October 2019 will address the challenges from drug discovery to commercialization. Pharma and biotech will present and share their expertise on how to make smart decisions about identifying novel biomarkers, clinical trial design, assays, technology platforms and CDx development.



Key Sessions

  • Emerging Biomarkers
  • Clinical Advances
  • CDx development and commercialization
  • Novel technologies to aid biomarker identification

Attendee Profile

Expect to meet the Who's Who of the industry at this unique event.

Pharmaceutical Companies
  • Biomarker Discovery
  • Biomarker Operations
  • Translation Sciences
  • Translational Medicine
  • Precision Medicine
  • Companion Diagnostics
  • Oncology
  • Immuno-Oncology
  • Bioanalysis
  • Genomics

Facts You Should Know

25+ Industry expert speakers from public and private sectors
150+ Attendees
7+ Hours of Networking
Case Studies Focused case studies

Silver Sponsor

Media Partners


Category Pricing
Industry Delegate(Pharmaceutical & Biopharmaceutical Companies) $349
Academic Delegate (Research Institutes, Hospitals & Universities) $249
Vendor Delegate (Technology & Solution Provider Companies) $1499

Early bird discounts and 3 for 2 offer is available till 31st July 2019.

The conference fee includes*

  • All conference sessions
  • Lunches and refreshments
  • Access to exhibition room
  • Networking breaks
  • Conference workbook